Figure 3. BSHXD increases HOXA10 and αvβ3 integrin expression in endometriosis mouse model.

A: endometriosis mouse models were treated with dydrogesterone and different dose BSHXD, after 28 d treatment, the mice were mated. The pregnant mice were euthanized on the 14th day of gestation and the endometrium was subjected to immunohistochemical staining using HOXA10 antibody (× 100). A1: Control group; A2: Model group; A3: Dydrogesterone group; A4: Low dose BSHXD group; A5: Normal dose BSHXD group; A6: High dose BSHXD group. B: The endometrium was subjected to immunohistochemical staining using αvβ3 integrin antibody (× 100). B1: Control group; B2: Model group; B3: Dydrogesterone group; B4: Low dose BSHXD group; B5: Normal dose BSHXD group; B6: High dose BSHXD group. C: the intensity of HOXA10 staining was quantitated by using Image J software. D: the intensity of αvβ3 integrin staining was quantitated. E: the expression level of Hoxa10 was determined using RT-qPCR. F: the expression level of Itgb3 was determined by RT-qPCR. Control group: sham surgery mice were treated with water; Model group: endometriosis mouse models were treated with water; Dydrogesterone group: endometriosis mouse models were treated with dydrogesterone (3.03 mg·kg^-1·d^-1); Low dose BSHXD group: endometriosis mouse models were treated with low dose BSHXD (6.218 g·kg^-1·d^-1); Normal dose BSHXD group: endometriosis mouse models were treated with normal dose BSHXD (12.437 g·kg^-1·d^-1); High dose BSHXD group: endometriosis mouse models were treated with high dose BSHXD (24.873 g·kg^-1·d^-1). BSHXD: Bushen Huoxue decotion; HOXA10: Homeobox A10; αvβ3: alpha(v)beta(3) integrin; Itgb3: Integrin beta(3); RT-qPCR: real-time quantitative polymerase chain reaction; D-HSCORE: digital histological score; mRNA: messenger ribonucleic acid; ANOVA: analysis of variance. Statistical analysis was carried out using ANOVA tests among these groups. Data were presented as mean ± standard deviation (n = 7). Compared with the model group, ^aP < 0.05.